• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Receptors
You are here: Product Lines > Signal Transduction > Receptors
 
Toolbar - View Selection
 
 Items 160-180 of 1015 Page 9 of 51 Select Page: << 1 2 3 4 5 6 7 8 9 10  >>  
ALX-300-302 Revised 25-Feb-05
Palmitoyl-N-isopropylamide
Add to Clipboard
SYNONYMS PIA
N-Isopropyl-hexadecanamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Fatty Acid Amide Hydrolase [FAAH] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-300-302-M005   5 mg 63.00 USD Add To Cart
Product Specification
FORMULA: C19H39NO
MW: 297.5
CAS NUMBER: 189939-61-5
PURITY: ≥98%
APPEARANCE: Crystalline solid.
SOLUBILITY: Soluble in ethanol (20mg/ml) and dimethyl formamide (3mg/ml). PIA will be stable for at least 6 months in these solvents when stored at -20°C. PIA is sparingly soluble in aqueous buffers.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 2 years after receipt when stored at -20°C.

Product Description
Inhibitor of fatty acid amide hydrolase (FAAH) (IC50=12.8µM). Displays little binding to CB1 and CB2 receptors (IC50>100µM) and very weakly blocks anandamide uptake (IC50~100µM).
Product Specific Literature References
Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide: K.O. Jonsson, et al.; Br. J. Pharmacol. 133, 1263 (2001) Abstract
AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide: K.O. Jonsson, et al.; Arch. Toxicol. 77, 201 (2003) Abstract
Further Categories Containing This Product:
Anandamide Uptake Inhibitors
 
 
ALX-340-041 Revised 11-Dec-07
Olvanil
Add to Clipboard
SYNONYMS NE-19550
N-Vanillyloleoylamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY TRPV1 Agonists and Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-041-M005   5 mg 30.00 USD Add To Cart
ALX-340-041-M010   10 mg 48.00 USD Add To Cart
Product Specification
FORMULA: C26H43NO3
MW: 417.6
CAS NUMBER: 58493-49-5
PURITY: ≥98%
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in 100% ethanol, chloroform, dimethyl formamide or DMSO.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
"Hybrid" activator of CB1 receptor (CB1: Ki=1.6µM; CB2: Ki=15µM) and TRPV1 (Ki=0.4µM; EC50=33nM (human); EC50=6.71nM (rat)). Also inhibits anandamide uptake (IC50=9µM, Ki=14.1µM) and fatty acid amide hydrolase (FAAH) (IC50=20µM).
Product Specific Literature References
NE-19550: a novel, orally active anti-inflammatory analgesic: L. Brand, et al.; Drugs Exp. Clin. Res. 13, 259 (1987) Abstract
The antinociceptive effect and pharmacokinetics of olvanil following oral and subcutaneous dosing in the mouse: W.K. Sietsema, et al.; Life Sci. 43, 1385 (1988) Abstract
Olvanil: more potent than capsaicin at stimulating the efferent function of sensory nerves: S.R. Hughes, et al.; Eur. J. Pharmacol. 219, 481 (1992) Abstract
Interactions between synthetic vanilloids and the endogenous cannabinoid system: V. Di Marzo, et al.; FEBS Lett. 436, 449 (1998) Abstract
Anandamide transport inhibition by the vanilloid agonist olvanil: M. Beltramo & D. Piomelli; Eur. J. Pharmacol. 364, 75 (1999) Abstract
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors: D. Melck, et al.; BBRC 262, 275 (1999) Abstract
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide: P.M. Zygmunt, et al.; Nature 400, 452 (1999) Abstract
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity: L. De Petrocellis, et al.; FEBS Lett. 483, 52 (2000) Abstract
Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology: J.C. Jerman, et al.; Br. J. Pharmacol. 130, 916 (2000) Abstract
Evidence against the presence of an anandamide transporter: S.T. Glaser, et al.; PNAS 100, 4269 (2003) Abstract
Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1: E. Phillips, et al.; J. Biol. Chem. 279, 17165 (2004) Abstract
Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors: J.W. Kasckow, et al.; Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 291 (2004) Abstract
Further Categories Containing This Product:
Anandamide Uptake Inhibitors • Cannabinoid Receptor Agonists & Antagonists / Related Products • Fatty Acid Amide Hydrolase [FAAH] / Related Products
 
 
ALX-340-042 Revised 07-Jan-06
Arvanil
Add to Clipboard
SYNONYMS N-[(4-Hydroxy-3-methoxyphenyl)methyl]-5Z,8Z,11Z,14Z-eicosatetraenamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Cannabinoid Receptor Agonists & Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-042-M005   5 mg 25.00 USD Add To Cart
Product Specification
FORMULA: C28H41NO3
MW: 439.6
CAS NUMBER: 128007-31-8
PURITY: ≥98%
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Protect from light. Keep cool and dry.

Product Description
"Hybrid" activator of CB1 receptor (CB1: Ki=0.5µM; CB2: Ki=>15µM) and TRPV1 (Ki=0.3µM). Also inhibits anandamide uptake (IC50=3.6µM) and fatty acid amide hydrolase (FAAH) (IC50=3µM). Analgesic, vasodilatory and anti-inflammatory in vivo. Apoptosis inducer.
Product Specific Literature References
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors: D. Melck, et al.; BBRC 262, 275 (1999) Abstract
Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide: V. Di Marzo, et al.; Eur. J. Pharmacol. 406, 363 (2000) Abstract
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid: V. Di Marzo, et al.; J. Pharmacol. Exp. Ther. 300, 984 (2002) Abstract
The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway: R. Sancho, et al.; Br. J. Pharmacol. 140, 1035 (2003) Abstract
Evidence against the presence of an anandamide transporter: S.T. Glaser, et al.; PNAS 100, 4269 (2003) Abstract
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease: E. de Lago, et al.; Brain Res. 1050, 210 (2005) Abstract
Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis: A.M. Malfitano, et al.; J. Neuroimmunol. 171, 110 (2006) Abstract
Further Categories Containing This Product:
Anandamide Uptake Inhibitors • Apoptosis Inducers & Inhibitors Other Products • TRPV1 Agonists and Antagonists / Related Products • Analgesic / Anti-nociceptive Agents / Related Products • Anti-inflammatory Agents Other Products • Fatty Acid Amide Hydrolase [FAAH] / Related Products
 
 
ALX-340-044 Revised 04-Feb-05
Linvanil
Add to Clipboard
PRODUCT LINE Neurobiology
PRODUCT CATEGORY TRPV1 Agonists and Antagonists / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-044-M005   5 mg 130.00 USD Add To Cart
Product Specification
FORMULA: C26H39NO3
MW: 413.6
PURITY: ≥92%
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Keep under inert gas. Protect from light.

Product Description
Ligand of TRPV1 with low affinity to CB1 receptor (Ki=3.4µM). Also inhibits anandamide uptake (IC50=8.0µM).
Product Specific Literature References
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors: D. Melck, et al.; BBRC 262, 275 (1999) Abstract
Anandamide uptake by human endothelial cells and its regulation by nitric oxide: M. Maccarrone, et al.; J. Biol. Chem. 275, 13484 (2000) Abstract; Full Text
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity: L. De Petrocellis, et al.; FEBS Lett. 483, 52 (2000) Abstract
Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues: V. Di Marzo, et al.; Eur. J. Pharmacol. 420, 123 (2001) Abstract
The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors: T. Bisogno, et al.; Eur. J. Biochem. 268, 1982 (2001) Abstract
Further Categories Containing This Product:
Cannabinoid Receptor Agonists & Antagonists / Related Products • Anandamide Uptake Inhibitors
 
 
ALX-340-046 Revised 12-Apr-07
VDM11
Add to Clipboard
SYNONYMS N-Arachidonoyl-4-hydroxy-2-methylaniline
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide Uptake Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-046-M001   1 mg 55.00 USD Add To Cart
ALX-340-046-M005   5 mg 220.00 USD Add To Cart
Product Specification
FORMULA: C27H39NO2
MW: 409.6
PURITY: ≥99%
APPEARANCE: Oil.
SOLUBILITY: Soluble in methanol, 100% ethanol or DMSO.
SHIPPING: SHIPPED ON DRY ICE
LONG TERM STORAGE: -20°C
HANDLING: Keep under inert gas.

Product Description
Selective inhibitor of anandamide uptake (neuronal (C6 glioma cells): IC50=11µM; non-neuronal (rat RBL-2H3 cells): IC50=7.2µM) with negligible action at TRPV1 and weak action at CB1 receptor (CB1: Ki=5µM; CB2: Ki>5µM) and FAAH (IC50=3.7µM/ IC50>50µM (N18TG2 cell membranes).
Product Specific Literature References
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity: L. De Petrocellis, et al.; FEBS Lett. 483, 52 (2000) Abstract
Endocannabinoids control spasticity in a multiple sclerosis model: D. Baker, et al.; FASEB J. 15, 300 (2001) Abstract; Full Text
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism: L. De Petrocellis, et al.; J. Biol. Chem. 276, 12856 (2001) Abstract; Full Text
Exogenous anandamide protects rat brain against acute neuronal injury in vivo: M. van der Stelt, et al.; J. Neurosci. 21, 8765 (2001) Abstract
Endocannabinoids as physiological regulators of colonic propulsion in mice: L. Pinto, et al.; Gastroenterology 123, 227 (2002) Abstract
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission: P. Gubellini, et al.; J. Neurosci. 22, 6900 (2002) Abstract
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism: L. De Petrocellis, et al.; J. Biol. Chem. 276, 12856 (2001) Abstract
 
 
ALX-340-048 Revised 13-Dec-04
VDM13
Add to Clipboard
SYNONYMS N-Arachidonoyl-5-methoxytryptamine
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide Uptake Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-048-M001   1 mg 75.00 USD Add To Cart
ALX-340-048-M005   5 mg 300.00 USD Add To Cart
Product Specification
FORMULA: C31H44N2O2
MW: 476.1
PURITY: ≥99%
APPEARANCE: Oil.
SOLUBILITY: Soluble in methanol, 100% ethanol or DMSO.
SHIPPING: SHIPPED ON DRY ICE
LONG TERM STORAGE: -20°C
HANDLING: Keep under inert gas.

Product Description
Selective inhibitor of anandamide uptake (neuronal (C6 glioma cells): IC50=12µM; non-neuronal (rat RBL-2H3 cells): IC50=12µM) with negligible action at TRPV1 and weak action at CB1 receptor (CB1: Ki>5µM; CB2: Ki>5µM) and FAAH (IC50=27µM).
Product Specific Literature References
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity: L. De Petrocellis, et al.; FEBS Lett. 483, 52 (2000) Abstract
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism: L. De Petrocellis, et al.; J. Biol. Chem. 276, 12856 (2001) Abstract; Full Text
Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists: D.A. Andersson, et al.; Mol. Pharmacol. 62, 705 (2002) Abstract
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism: L. De Petrocellis, et al.; J. Biol. Chem. 276, 12856 (2001) Abstract
 
 
ALX-340-064 Revised 10-Jul-08
AM 1172
Add to Clipboard
SYNONYMS N-5Z,8Z,11Z,14Z-Eicosatetraenyl-4-hydroxy-benzamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide Uptake Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-340-064-M001   1 mg 57.00 USD Add To Cart
ALX-340-064-M005   5 mg 254.00 USD Add To Cart
Product Specification
FORMULA: C27H39NO2
MW: 409.6
CAS NUMBER: 251908-92-6
PURITY: ≥98%
FORMULATION: Liquid. Solution in ethanol.
SOLUBILITY: 30mg/ml soluble in DMSO or dimethyl formamide; sparingly soluble in PBS, pH 7.2 (0.15mg/ml).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored at -20°C. We do not recommend storing aqueous solutions for more than one day.

Product Description
Potent and selective inhibitor of anandamide uptake, resistant to fatty acid amide hydrolase (FAAH) hydrolysis. Metabolically stable “reversed” isomer of AM 404 (Prod. No. ALX-340-032).
Product Specific Literature References
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172: D. Fegley, et al.; PNAS 101, 8756 (2004) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION To change the solvent, evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice.
Related Products
 
 
ALX-430-152 Revised 03-Apr-08
Cannabidiol
Add to Clipboard
SYNONYMS CBD
2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products for Neurological Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-430-152-M001   1 mg Inquire
ALX-430-152-M005   5 mg Inquire
Product Specification
FORMULA: C21H30O2
MW: 314.5
CAS NUMBER: 13956-29-1
MERCK INDEX: 14: 1747
RTECS: VH1600000
SOURCE/HOST: Natural product.
PURITY: ≥98% (HPLC)
APPEARANCE: White to pale yellow powder.
SOLUBILITY: Soluble in DMSO, 100% ethanol or methanol; insoluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Non-psychotropic, anticonvulsive and neuroprotective in vivo. Shown to be a weak CB1 receptor antagonist and inhibitor of anandamide uptake (IC50=3.35mM and 27.5mM, respectively). Weak agonist of TRPV1 (EC50=3.5mM).
Product Specific Literature References
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants: A.J. Hampson, et al.; PNAS 95, 8268 (1998) Abstract; Full Text
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis: A.M. Malfait, et al.; PNAS 97, 9561 (2000) Abstract; Full Text
Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite: A.B. El-Remessy, et al.; Am. J. Pathol. 163, 1997 (2003) Abstract; Full Text
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines: P. Massi, et al.; J. Pharmacol. Exp. Ther. 308, 838 (2004) Abstract; Full Text
Effects of cannabidiol (CBD) on regional cerebral blood flow: J.A. Crippa, et al.; Neuropsychopharmacology 29, 417 (2004) Abstract; Full Text
Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression: E.J. Carrier, et al.; PNAS 103, 7895 (2006) Abstract; Full Text
Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells: E. Del Giudice, et al.; J. Leukoc. Biol. 81, 1512 (2007) Abstract; Full Text
Further Categories Containing This Product:
Anandamide Uptake Inhibitors • Cannabinoid Receptor Agonists & Antagonists / Related Products • TRPV1 Agonists and Antagonists / Related Products • Natural Products - Antioxidants
 
 
ALX-550-386 Revised 29-Jan-05
OMDM-1
Add to Clipboard
SYNONYMS (S)-N-Oleyl tyrosinol
(S)-N-(1-(4-Hydroxyphenyl)-2-hydroxyethyl)oleamide
PRODUCT LINE Neurobiology
PRODUCT CATEGORY Anandamide Uptake Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-550-386-M005   5 mg 85.00 USD Add To Cart
Product Specification
FORMULA: C27H45NO3
MW: 431.7
PURITY: ≥98%
APPEARANCE: White to off-white crystalline solid.
SOLUBILITY: Soluble in 100% ethanol, dimethyl formamide or DMSO; also soluble in a 1:1 solution of ethanol:PBS.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 2 years after receipt when stored at -20°C. We do not recommend storing the aqueous solution for more than one day.

Product Description
Metabolically stable, potent inhibitor of cellular anandamide uptake (neuronal (C6 glioma cells): IC50=2.6µM; non-neuronal (rat RBL-2H3 cells): IC50>20µM) with negligible effects on CB1 receptor (CB1: Ki=12.1µM; CB2: Ki>10µM), TRPV1 (EC50>10µM) and FAAH (IC50>100µM).
Product Specific Literature References
Novel selective and metabolically stable inhibitors of anandamide cellular uptake: G. Ortar, et al.; Biochem. Pharmacol. 65, 1473 (2003) Abstract
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle: C.J. Fowler, et al.; Eur. J. Pharmacol. 492, 1 (2004) Abstract
Further evidence for the existence of a specific process for the membrane transport of anandamide: A. Ligresti, et al.; Biochem. J. 380, 265 (2004) Abstract
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake: E. de Lago, et al.; Eur. J. Pharmacol. 484, 249 (2004) Abstract
 
 
ALX-550-387 Revised 04-Mar-05